Eloxx Presents More Positive Preclinical Data for ELX-02, Potential CF Treatment
Mar 29, 2019 07:00 am | Ana Pena
Eloxx Pharmaceuticals presented new positive preclinical data for ELX-02, its lead treatment candidate for cystic fibrosis (CF), demonstrating that the therapy increases the levels of CFTR protein and its correct placement at the cell’s surface in patient-derived organoids. Findings were presented by Shira Landskroner-Eiger, PhD, Eloxx’s principal scientist at the 2019 European Cystic Fibrosis Society (ECFS) […]
The post Eloxx Presents More Positive Preclinical Data for ELX-02, Potential CF Treatment appeared first on Cystic Fibrosis News Today.